Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Akebia sells rights to anemia drug to Otsuka

Drug developer Akebia Therapeutics Inc. said it had signed a co-development and marketing deal worth up to $1 billion with Japan’s Otsuka Holdings Co. Ltd.

Read More »

Your Ph.D. From the School of Life Is Just as Important as That STEM Degree

Medical startups must successfully mix entrepreneurial knowledge, a STEM-steeped education, and real-life experience to have the type of lasting impact they desire.

Read More »

Neos Therapeutics resubmits ADHD drug marketing application

Drug developer Neos Therapeutics Inc. said it resubmitted the marketing application for its attention deficit/hyperactivity disorder (ADHD) drug to the U.S. Food and Drug Administration.

Read More »

Acadia Stock Screams Upward; Primary Endpoint Met in Phase II Study of Pimavanserin for Alzheimer’s

Shares of Acadia Pharmaceuticals were soaring after the company announced its mid-stage drug pimavanserin to treat patients with Alzheimer’s disease psychosis hit its trial endpoints.

Read More »

Bristol-Myers Squibb, PsiOxus Therapeutics Reach Deal for “Armed” Oncolytic Virus

PsiOxus Therapeutics Ltd. agreed to grant Bristol-Myers Squibb Co. exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors.

Read More »

Laser therapy with deep-sea drug kills prostate cancer in trial

A non-surgical treatment for low-risk prostate cancer in which doctors inject a light-sensitive drug derived from deep-sea bacteria into a patient’s bloodstream was shown in a trial to kill cancer cells without destroying healthy tissue.

Read More »

FDA grants accelerated approval to Clovis’ ovarian cancer drug

The U.S. Food and Drug Administration said it approved Clovis Oncology Inc.’s ovarian cancer drug.

Read More »

GSK boosts board-level science as new CEO prepares to take over

Drugmaker GlaxoSmithKline is bolstering scientific expertise on its board by establishing a new science committee, charged with overseeing research, as a new chief executive prepares to take over.

Read More »

Japan to review drug prices annually rather than every two years: sources

The Japanese government plans to start reviewing drug prices every year – instead of every two years – to try to reduce mounting healthcare costs, government officials with direct knowledge of the decision said.

Read More »

Rare metabolic disorder drug succeeds key study

Ionis Pharmaceuticals Inc. said its rare metabolic disorder drug for severe hypertriglyceridemia met the main goal in a late-stage study.

Read More »

White House Kills Plan for Drug Price Cap

Big pharma got an early Christmas present after the Obama administration terminated a controversial plan to combat high drug prices.

Read More »

AstraZeneca PLC Exec Jumps Ship to Become Innate Pharma CEO

Mondher Mahjoub, the head of AstraZeneca’s oncology programming, has jumped ship and will now helm France-based Innate Pharma.

Read More »

Richter withdraws biosimilar marketing application

Hungarian pharma firm Richter withdrew a marketing application for a biosimilar drug from the EMA in anticipation of a possible negative assessment.

Read More »

Mylan launches EpiPen generic at $300 per 2-pack

Mylan, which has come under fire for its drug pricing, will sell a generic version of its life-saving EpiPen allergy treatment at a more than 50 percent discount.

Read More »

An Abandoned Pfizer Drug Turns People Into ‘Zombies’

Zombies. They are arguably the most popular monsters in pop culture these days, but a synthetic cannabinoid originally developed by Pfizer has been linked to drug overdoses that led some observers to describe the victims as “zombielike.”

Read More »

Cambridge Biotech Agios Terminates AG-519 for PK Deficiency, But Continues AG-348 For Same Condition

Agios Pharmaceuticals announced that after a verbal notification from the U.S. Food and Drug Administration of a clinical hold on its clinical trial of AG-519, it is withdrawing its investigational new drug (IND) application and halting the program.

Read More »

New York’s Cellectis Looks to 2017 for Clinical Trials of AML Treatment

Cellectis is ending 2016 on a roll. The company is closing out the year with a series of successful runs of its Phase I candidate for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), UCART123. The runs met cGMP standards.

Read More »

Novartis buys Ziarco, expands skin care portfolio

Novartis is buying privately held drugmaker Ziarco Group for an undisclosed sum to gain access to its investigational eczema medicine.

Read More »

Merck wins $2.54 billion in hepatitis C drug trial

Merck & Co. was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit over Gilead Sciences’ blockbuster hepatitis C drugs Sovaldi and Harvoni.

Read More »

U.S. says Allergan’s Forest units to pay $38 million to settle kickback allegations

Allergan PLC’s Forest Laboratories and Forest Pharmaceuticals units will pay $38 million to settle U.S. charges that it paid physicians to prescribe three medications, the U.S. Justice Department said.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom